PPARα
PPARα is a ligand-activated nuclear receptor that controls fatty acid metabolism in oxidative tissues, especially liver, heart, and muscle[1]. Mechanistically, hepatocyte PPARα acts as a lipid sensor that coordinates fasting-responsive gene networks for fatty acid homeostasis, ketogenesis, and metabolic adaptation[2]. In disease models, liver PPARα protects against NAFLD by supporting whole-body fatty acid homeostasis, while combined PPARα and PPARβ/δ activation improves steatosis, inflammation, and fibrosis in preclinical liver disease models[3][1]. Compared with related isoforms, PPARα primarily promotes fatty acid catabolism, whereas PPARγ favors fatty acid uptake, triglyceride storage, insulin sensitivity, and glucose metabolism[4][5]. For experimental applications, fibrates and WY-14,643 serve as PPARα agonists, while GW6471 supports antagonist-based studies by stabilizing corepressor recruitment to the PPARα ligand-binding domain[6][7].
References:
- [1]. Pawlak M, et al. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015 Mar;62(3):720-33. [Content Brief]
- [2]. Fougerat A, et al. Lipid sensing by PPARα: Role in controlling hepatocyte gene regulatory networks and the metabolic response to fasting. Prog Lipid Res. 2024 Nov;96:101303. [Content Brief]
- [3]. Montagner A, et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut. 2016 Jul;65(7):1202-14. [Content Brief]
- [4]. Wang YX. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res. 2010 Feb;20(2):124-37. doi: 10.1038/cr.2010.13. Epub 2010 Jan 26. PMID: 20101262; PMCID: PMC4084607. et al. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res. 2010 Feb;20(2):124-37. [Content Brief]
- [5]. Montaigne D, et al. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021 Dec;18(12):809-823. [Content Brief]
- [6]. Oike Y, et al. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med. 2005 Oct;11(10):473-9. [Content Brief]
- [7]. Xu HE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature. 2002 Feb 14;415(6873):813-7. [Content Brief]
-
PPARα Related Products (139)
Related Products (139)
-
Recombinant Proteins (2)
-
Antibodies (1)
-
PPARα agonist 6
0 ImagesPPARα agonist 6 (Compound 15) is a PPARα agonist. PPARα agonist 6 can be used in the research of dyslipidemia.
-
Eupatilin (Standard)
0 ImagesEupatilin (Standard) is the analytical standard of Eupatilin. This product is intended for research and analytical applications. Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.
-
13-Oxo-9E,11E-octadecadienoic acid
0 ImagesCat. No.: HY-N5097CAS No.: 29623-29-813-Oxo-9E,11E-octadecadienoic acid, an isomer of 9-oxo-ODA, is a potent PPARα activator derived from tomato juice. 13-Oxo-9E,11E-octadecadienoic acid decreases plasma and hepatic triglyceride in obese diabetic mice.
-
PPAR agonist 1
0 ImagesPPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
-
Chiglitazar sodium
0 ImagesSynonyms: Carfloglitazar sodium
-
Tibric acid
0 ImagesCat. No.: HY-121755CAS No.: 37087-94-8Synonyms: CP 18524Tibric acid (CP 18524) has similar effects to those of hypolipidemic agents. Tibric acid has orally active triglyceride-lowering effects. Tibric acid can be used for research of hypertriglyceridemia.
-
9(S)-HOTrE
0 Images9(S)-HOTrE is a PPARα activator and an inducer of apolipoprotein A-I (apoA-I) mRNA expression. 9(S)-HOTrE upregulates the expression of PPARα target gene CPT1α. 9(S)-HOTrE can be used in the research of cardiovascular diseases.
-
Norbixin
0 ImagesCat. No.: HY-W587784CAS No.: 542-40-5Norbixin is an orally active natural product with multiple activities such as retinal protection and oxidative stress regulation. Norbixin scavenges ROS, chelates metal ions, regulates plasmid and genomic DNA breakage, inhibits H2O2-induced mutagenesis, activates PPAR-α, modulates lipid levels, restores or regulates antioxidant enzyme activity, and alters NO levels. Norbixin prevents A2E accumulation and protects photoreceptor cells and retinal pigment epithelial cells. Norbixin is a derivative of Bixin (HY-N6884). Norbixin can be used in research related to diseases such as macular degeneration and diabetes, and also serves as a natural textile dye.
-
PPARα agonist 2
0 ImagesCat. No.: HY-139177CAS No.: 2376590-40-6PPARα agonist 2 (compound 4u) is a potent and selective PPARα agonist with an EC50 of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research.
-
ABP/PPAR modulator 1
0 ImagesCat. No.: HY-172883CAS No.: 3104894-76-7ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC50s of 0.65 μM and 1.08 μM for FABP1 and FABP4, EC50 s of 9.19 μM, 2.20 μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model.
-
Pioglitazone potassium
0 ImagesCat. No.: HY-13956BCAS No.: 1266523-09-4Synonyms: U 72107 potassiumPioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research.
-
Ciprofibrate impurity A
0 ImagesCat. No.: HY-133777CAS No.: 1474058-89-3Ciprofibrate impurity A is an impurity of Ciprofibrate. Ciprofibrate (Win35833) is a potent peroxisome proliferator, increases the phosphorylation level of the PPARalpha.
-
BMS711939
0 ImagesCat. No.: HY-115357CAS No.: 1000998-62-8BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC50 of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides.
-
NO-Pravastatin
0 ImagesCat. No.: HY-184354CAS No.: 733034-46-3NO-Pravastatin is a derivative of Pravastatin (HY-B0165) covalently linked with an NO donor moiety, endowing it with dual functions of HMG-CoA reductase (HMGCR) inhibition and exogenous nitric oxide (NO) release. NO-Pravastatin activates PPARα/γ and ABCA1, and inhibits LPS (HY-D1056)-induced TNFα production. NO-Pravastatin can be used in research related to gallstones and cardiovascular diseases.
-
Esculeogenin A
0 ImagesCat. No.: HY-N18066CAS No.: 854381-37-6Esculeogenin A is the sapogenol of tomato saponin Esculeoside A (HY-N18067). Esculeogenin A is an orally active hepatoprotective, hypolipidemic, and antioxidant agent. Esculeogenin A regulates molecular targets like PPARα, SREBP1, Nrf2, NF-κB, ACAT1/ACAT2 to promote hepatic fatty acid oxidation, suppress de novo lipogenesis, enhance antioxidant defense, and inhibit inflammation. Esculeogenin A improves liver function, alleviates hyperlipidemia, and inhibits hepatic steatosis and foam cell formation, preventing nonalcoholic fatty liver disease in high-fat-diet-fed rats and reducing atherosclerotic lesions in apoE-deficient mice. Esculeogenin A can be used for the research of nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia.
-
PPAR agonist 4
0 ImagesCat. No.: HY-163443PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC50s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy.
-
LJ570
0 ImagesCat. No.: HY-111775CAS No.: 2252488-69-8
-
PPAR agonist 8
0 ImagesCat. No.: HY-184312CAS No.: 1031072-40-8PPAR agonist 8 is an orally active pan-PPAR agonist, with KD values of 0.576 μM, 2.06 μM and 1.45 μM for PPARα, PPARγ and PPARδ, respectively. PPAR agonist 8 upregulates the expression of ATP-binding cassette transporter A1 (ABCA1) and promotes cholesterol efflux. PPAR agonist 8 reduces plasma cholesterol levels, decreases cholesterol accumulation in the liver and cholesterol deposition in pancreatic islets, regulates glucose and lipid metabolism, and causes no side effects of weight gain and obesity. PPAR agonist 8 can be used in the research of type 2 diabetes, hepatic steatosis and pancreatic islet dysfunction.
